Ignite Creation Date:
2024-05-05 @ 7:24 PM
Last Modification Date:
2024-10-26 @ 9:48 AM
Study NCT ID:
NCT00669305
Status:
COMPLETED
Last Update Posted:
2020-02-25
First Post:
2008-04-28
Brief Title:
Bone Marrow for Hemoglobinopathy Research
Sponsor:
St Jude Childrens Research Hospital
Organization:
St Jude Childrens Research Hospital
Study Overview
Official Title:
Bone Marrow for Hemoglobinopathy Research
Status:
COMPLETED
Status Verified Date:
2020-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Human participants affected with sickle cell disease or thalassemia will donate bone marrow for use in experimental laboratory models to study potential new treatments This is an observational study using bone marrow from human participants The investigators will use sickle cell and thalassemia mouse models to observe and evaluate the possibility of correcting these disorders through genetic alterations or drug treatment
Detailed Description:
These studies are designed to evaluate the potential of retroviral vector mediated gene transfer gene editing or drug treatment to correct the pathophysiology of sickle cell anemia and β-thalassemia CD34 cells purified from bone marrow of research participants with a sickle cell syndrome or a thalassemia syndrome will be subjected to genetic editing drug treatment or transduced with retroviral vectors containing γ-globin coding sequences under the control of the β-globin gene promoter and including various regulatory elements chosen to enhance gene expression and to insulate regulatory elements from cellular genes at or near the integration sites The efficiency of gene transfer and the function of the globin transgene will be evaluated in erythroid cells derived from transduced progenitors and from the progenitors in the bone marrow of immunodeficient mice engrafted with transduced primitive hematopoietic cells The hypothesis to be tested in this research is that a gene therapy vector gene editing strategy or drug modality can be designed to achieve a potentially therapeutic level of globin gene expression in maturing erythroid cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 201003 | OTHER | Doris Duke Foundation | httpsreporternihgovquickSearchP01HL053749 |
| U54HL070590 | NIH | None | None |
| P01HL053749 | NIH | None | None |